Francisco Gimenez

Eight Enterprises LLC (8VC) is a private equity/venture capital firm founded in 2015 by Joseph T. Lonsdale. The firm is headquartered in San Francisco, California.

BlueVoyant LLC engages in the provision of cybersecurity services. It offers third party cyber risk service, managed security services, threat intelligence, and professional services. The company was founded by Thomas Henry Glocer and James A. Rosenthal in July 2017 and is headquartered in New York, NY.

Appia Bio, Inc. is an early stage biotechnology company based in an undisclosed location. Appia Bio is focused on discovering and developing engineered allogeneic cell therapies across a broad array of indications with a scalable technology platform that increases access for patients. The American company utilizes the biology of lymphocyte development with chimeric antigen receptor (CAR) and T cell receptor (TCR) gene engineering to generate CAR-engineered invariant natural killer T (CAR-NKT) or gamma delta T cells from hematopoietic stem cells (HSCs) with its ACUA (Appia Cells Utilized for Allogeneic) technology platform. The ACUA platform was developed from groundbreaking research in the laboratory of Lili Yang, Ph.D., at the University of California, and collaboration with Appia Bio's other scientific founders, David Baltimore, Ph.D. at Caltech and Pin Wang, Ph.D. at the University of Southern California. The company was founded in 2020 by Jeffrey S. Wiezorek, David Baltimore, Jeenjoo Kang, Lili Yang, Edmund Kim, and Pin Wang. Jeenjoo Kang has been the CEO since 2020.

Flywheel Exchange LLC develops cloud-based software which helps scientists and researchers to share data and algorithms. The firm also provides computer programming services. It offers life sciences, clinical research, imaging research and AI developer solutions. The company was founded by Brian Wandell, Troy D. Kopischke, Ryan Chamberlai and Gunnar Schaefer in 2012 and is headquartered in Minneapolis, MN.

Unlearn.AI, Inc. develops machine learning technology for clinical drug trails. It offers clinical trial design, synthetic control arms, and super-powered subgroup analysis. The company was founded by Aaron Smith, Charles K. Fisher, and Jonathan Walsh in 2017 and is headquartered in San Francisco, CA.

Mantra Bio, Inc. develops deep data platform for exosome discovery. It focuses on harnessing naturally occurring human exosomes to develop safe, ultra-targeted therapies to combat intractable diseases. The company is headquartered in San Francisco, CA.